Advisory boutique · United States

MTS Health Partners

Deals
4
M&A
3
Equity raisings
1
Latest
Aug 2026
Compare

Deals

Deals dated after 30 September 2026 are still being collected.

Columns
Deal size
Custom range

4 of 4 deals

Deals MTS Health Partners advised on, most recent first
Advisers
Aug 2026 Skye Bioscience ––PlacementPlacement agent to the lead managersAnnounced68.0Biotech+1 Leerink Partners (lead manager)Mintz (lead manager) Skye Bioscience placement
Jun 2026 Theravance Biopharma –ZymeworksAcquisitionFinancial adviser to Zymeworks (acquirer)Pending929.0Pharma+1 Lazard (sell-side)Evercore (sell-side)Skadden, Arps, Slate, Meagher & Flom (sell-side)Arthur Cox (sell-side)Kirkland & Ellis (buy-side)Matheson (buy-side) Zymeworks acquisition of Theravance Biopharma
May 2026 Cross Country Healthcare –Knox LaneAcquisitionFinancial adviser to Knox Lane (acquirer)Completed437.0Healthcare Staffing BofA Securities (sell-side)Davis Polk (sell-side)Kirkland & Ellis (buy-side) Knox Lane acquisition of Cross Country Healthcare
Jan 2026 Alma –Spring HealthAcquisitionFinancial adviser to Alma (target)Announced–Healthcare Software+1 Cooley (buy-side)Gunderson Dettmer (sell-side)J.P. Morgan (buy-side) Spring Health acquisition of Alma

Activity

Deals by year
MTS Health Partners: deals by year2025: 0, 2026 YTD: 40123420252026 YTD: 3 M&A2026 YTD: 1 Equity raisings42026 YTDM&AEquity raisings

By announcement date; raisings and IPOs by their own date.

Deals by sector
MTS Health Partners: deals by sectorBiotech1Healthcare Services1Healthcare Software1Pharma1

Sector of the business bought or funded.

Deals by size
MTS Health Partners: deals by sizeUnder US$100m1US$100–500m1US$500m–1bn1Undisclosed1

Disclosed value in US dollars.

Most often across the table

Firms advising the other side of the same deals.

Offices and contact

Contact

From the firm's own website.

Suggest a correction

A missing deal, a wrong role or an office to add. A link to a public source helps.